GlycoNex Completes Patient Dosing in Phase 3 Trial of Denosumab Biosimilar SPD8 for Osteoporosis
核心洞察
GlycoNex (搜索) announced the completion of patient dosing in its Phase 3 clinical study of SPD8, a biosimilar to denosumab for osteoporosis treatment.
The randomized, multicenter, double-blind study evaluates pharmacokinetic equivalence, efficacy, and safety of SPD8 compared to denosumab in postmenopausal women with primary osteoporosis.
Topline results are expected in the second quarter of 2026, with data supporting global regulatory registration.
GlycoNex (搜索), Inc. announced that the last patient has received the final dose in its Phase 3 clinical study of SPD8, a biosimilar to denosumab for the treatment of osteoporosis. The Taiwan-based biotechnology company, working in collaboration with Mitsubishi Gas Chemical (MGC), expects to report topline results from the study in the second quarter of 2026.
Phase 3 Trial Design and Objectives
The randomized, multicenter, double-blind, parallel-group study is evaluating the pharmacokinetic equivalence, efficacy, and safety of SPD8 compared to denosumab in postmenopausal women with primary osteoporosis from solid tumors. SPD8 is designed to address complications associated with bone metastases in patients with solid tumors and osteoporosis-related conditions.
The resulting data generated will support global registration of the biosimilar candidate. This milestone positions GlycoNex (搜索) to advance SPD8 toward regulatory submission as a cost-effective alternative for patients who rely on denosumab therapy.
Market Opportunity and Commercial Strategy
Denosumab, marketed as Prolia®/Xgeva®, generated $6.60 billion in global 2024 sales, underscoring sustained demand in osteoporosis and oncology-related bone indications. SPD8 has the potential to broaden patient access in areas where cost remains a barrier to treatment.
GlycoNex (搜索) has already out-licensed SPD8 for certain territories and remains in discussions with multiple additional companies regarding territory-specific development and commercialization collaborations.
Company Strategy and Leadership Perspective
"Achieving 'last patient, last dose' in our SPD8 Phase 3 study represents a critical milestone for GlycoNex (搜索)," said Dr. Mei-Chun Yang, CEO of GlycoNex. "With the trial now moving into its final phase of analysis, we are focused on advancing SPD8 toward regulatory submission and delivering a cost-effective alternative to patients who rely on denosumab therapy."
The SPD8 program reflects GlycoNex (搜索)'s broader strategy of leveraging its expertise in complex antibody manufacturing to deliver high-quality biosimilars in parallel with its efforts to develop novel glycan-directed antibody-drug conjugates. The company maintains a robust pipeline led by GNX102, a humanized monoclonal antibody designed to target abnormal sugar molecules in cancer cells, and is advancing a portfolio of antibody-drug conjugates including GNX1021, which targets branched Lewis B/Y (bLeB/Y).